Walter Chatham
Rheumatology · Las Vegas, NVNPI 1154363315
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (49.7%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 25 manufacturers reported payments, led by GSK at 37.8% of the total. 2025 is the largest year on record at $68,208, 7.6 times the $8,977 reported in 2019. Among rheumatology clinicians in NV with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 227 payments — averaging $867.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$74K
- Sobi, Inc$57K
- Aurinia Pharma U.S., Inc.$46K
- Amgen$6K
- AstraZeneca$6K
- Novartis$3K
- plus $5K from 19 others
Across 228 payments — averaging $8828.83 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$449K
- E.r. Squibb & Sons, L.L.C.$269K
- GSK$262K
- Amgen$223K
- Astrazeneca UK Limited$176K
- Janssen Research & Development, LLC$166K
- plus $468K from 12 others
What the payments were for
- Consulting fees$97,76850%
- Speaking & faculty fees$76,82439%
- Travel & lodging$14,0637%
- Food & beverage$8,1444%
- Education$580%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 55 | $74,493 |
| Sobi, Inc | 39 | $56,959 |
| Aurinia Pharma U.S., Inc. | 46 | $45,596 |
| Amgen | 19 | $5,929 |
| AstraZeneca(2 entities) | 15 | $5,543 |
| Novartis | 4 | $3,382 |
| Janssen Research & Development, LLC | 2 | $900 |
| AbbVie | 18 | $888 |
| Vertex | 1 | $475 |
| Pacira Pharmaceuticals Incorporated | 1 | $400 |
| ZOLL Medical Corporation | 1 | $373 |
| Tersera Therapeutics LLC | 1 | $373 |
| Kyowa Kirin, Inc. | 6 | $370 |
| Boehringer Ingelheim | 3 | $362 |
| UCB, Inc. | 3 | $260 |
| ANI Pharmaceuticals, Inc. | 1 | $119 |
| Sanofi | 1 | $119 |
| Kedrion Biopharma, Inc. | 1 | $96 |
| Lilly USA, LLC | 2 | $55 |
| Swedish Orphan Biovitrum AB | 2 | $43 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $35 |
| Mallinckrodt Hospital Products Inc. | 1 | $26 |
| Lundbeck LLC | 1 | $23 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $22 |
| Radius Health, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$196,857 in reported general payments places this provider in the 95th percentile of 43 rheumatology providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira PenAdalimumab | 12 | $115,892 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 12 | $87,482 |
| Humira(Cf) PenAdalimumab | 12 | $80,893 |
| OtezlaApremilast | 13 | $62,786 |
| Hydroxychloroquine Sulfate | 201 | $5,808 |
| MethotrexateMethotrexate Sodium | 98 | $1,687 |
| Leflunomide | 16 | $800 |
| Prednisone | 84 | $311 |
| Ibuprofen | 18 | $256 |
| Duloxetine Hcl | 15 | $233 |
| Colchicine | 11 | $228 |
| Folic Acid | 13 | $67 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenOtezla | $5,929 | $62,78613 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 43 rheumatology providers in Nevada.
Other rheumatology in Las Vegas
- Ewa OlechLas Vegas$287K
- George KellyLas Vegas$185K
- Nasim DaoudLas Vegas$109K
- William KimLas Vegas$16K
- Aida LoudyiLas Vegas$10K
- Tudor JianuLas Vegas$8K
- Khalil Ibrahim BourjiLas Vegas$7K
- Neil BraunsteinLas Vegas$6K
- Michael CliffordLas Vegas$4K
- Chen TangLas Vegas$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.